What is CohBar?
CohBar is a clinical-stage biotechnology company dedicated to the research and development of mitochondria-based therapeutics. These emerging drugs are designed to treat chronic and age-related diseases by leveraging naturally occurring peptide sequences found within the mitochondrial genome. The company's lead compound, CB4211, has completed Phase 1a/1b clinical trials for nonalcoholic steatohepatitis (NASH) and obesity. Additionally, CohBar is advancing four preclinical programs, including CB5138-3 for idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases, which is currently in IND-enabling studies. Other preclinical efforts target acute respiratory distress syndrome (ARDS), CXCR4-related cancers, and cancer immunotherapy.
How much funding has CohBar raised?
CohBar has raised a total of $11.3M across 1 funding round:
Stock Offering
$11.3M
Stock Issuance/Offering (2015): $11.3M, investors not publicly disclosed
What's next for CohBar?
The recent major strategic investment positions CohBar to accelerate its development pipeline, particularly for its lead compound CB4211 and its preclinical candidates targeting fibrotic diseases, ARDS, and cancer. This capital infusion is expected to fuel further clinical trials and IND-enabling studies, advancing CohBar's mission to address a broad spectrum of diseases linked to mitochondrial dysfunction. The company's focus on a novel therapeutic class derived from the mitochondrial genome suggests a strategic push into a potentially groundbreaking area of medicine.
See full CohBar company page
